MiNK Therapeutics Inc. Common Stock (INKT)
Stock · NASDAQ · Health Care
$9.41as of 10/16/2026
Price chart
Active signals
INKT Signal Track Record
How signals performed across all stocks →What INKT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band BreakdownActive now | 21 | -0.3% | 43% | October 8, 2026 |
| Bollinger Band Breakout | 22 | -16.6% | 14% | August 21, 2026 |
| 200-Day Moving Average TouchActive now | 15 | +0.6% | 53% | October 7, 2026 |
| Volume Spike | 14 | -9.5% | 21% | September 30, 2026 |
| Any 20-session window (baseline) | -3.3% | 39% |
Computed by MarketWall from daily closing prices since August 2, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About INKT
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 15
- Website
- www.minktherapeutics.com
Fundamentals
- 1-day range
- $9.93$10.35
- Market cap
- $54.80M
- P/E (trailing)
- —
- P/E (forward)
- -5.05
- EPS (trailing)
- $-2.40
- Dividend yield
- —
- Beta
- 0.45
- Avg. volume
- 13.8K
Forecasts
2 analyst ratings
MiNK Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- INKTMiNK Therapeutics Inc. Common Stock$9.41▼ 5.33%Market cap $54.80MP/E —$8.48$16.93
- OKYOOKYO Pharma Limited Ordinary Shares$1.41▼ 1.40%Market cap $51.94MP/E —$1.26$3.2
- INMBINmune Bio Inc. Common stock$1.57▼ 4.85%Market cap $50.78MP/E —$1.09$2.6
- SCLXScilex Holding Company Common Stock$2.83▲ 0.35%Market cap $58.93MP/E —$2.77$27
- TCRXTScan Therapeutics Inc. Common Stock$0.231▼ 3.35%Market cap $49.88MP/E —$0.2243$2.57
- TILInstil Bio Inc. Common Stock$5.91▼ 3.59%Market cap $49.37MP/E —$5.67$21.64
- ATYRaTyr Pharma Inc. Common Stock$0.174▼ 5.43%Market cap $49.22MP/E —$0.2$1.11
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| INKT MiNK Therapeutics Inc. Common Stock | $54.80M | — | $9.41 | ▼ 5.33% | $8.48$16.93 |
| OKYO OKYO Pharma Limited Ordinary Shares | $51.94M | — | $1.41 | ▼ 1.40% | $1.26$3.2 |
| INMB INmune Bio Inc. Common stock | $50.78M | — | $1.57 | ▼ 4.85% | $1.09$2.6 |
| SCLX Scilex Holding Company Common Stock | $58.93M | — | $2.83 | ▲ 0.35% | $2.77$27 |
| TCRX TScan Therapeutics Inc. Common Stock | $49.88M | — | $0.231 | ▼ 3.35% | $0.2243$2.57 |
| TIL Instil Bio Inc. Common Stock | $49.37M | — | $5.91 | ▼ 3.59% | $5.67$21.64 |
| ATYR aTyr Pharma Inc. Common Stock | $49.22M | — | $0.174 | ▼ 5.43% | $0.2$1.11 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026Yahoo · 10/2/2026
- MiNK Therapeutics Says agenT-797 Selected As Cell Platform For Draper-Led Team In ARPA-H Room-Temperature Storage Programbenzinga · 9/30/2026
- MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell TherapyYahoo · 9/30/2026
Insider Activity
Insider Actions →- John Bradley Holcomb · September 1, 2026 · Grant1.2K @ $10.95
- Peter Behner · September 1, 2026 · Grant1.5K @ $10.95
- Barbara Ryan · September 1, 2026 · Grant1.6K @ $10.95
- Brian Corvese · September 1, 2026 · Grant1.6K @ $10.95
- Ulf Wiinberg · September 1, 2026 · Grant1.3K @ $10.95
- Barbara Ryan · June 4, 2026 · Sale1.0K @ $12.8
- Barbara Ryan · June 4, 2026 · Sale500 @ $12.68
- Brian Corvese · June 1, 2026 · Grant1.4K @ $12.38
- Ulf Wiinberg · June 1, 2026 · Grant1.1K @ $12.38
- John Bradley Holcomb · June 1, 2026 · Grant1.1K @ $12.38
- Peter Behner · June 1, 2026 · Grant1.3K @ $12.38
- Barbara Ryan · June 1, 2026 · Grant1.4K @ $12.38
Institutional Ownership
March 31, 2026
- Total shares held
- 117.5K
- Total value held
- $1.24M
- Institutional holders
- 20
- Unknown59.4K
- Unknown17.3K
- Unknown16.7K
- Unknown15.2K
- Unknown6.2K
- Unknown2.0K
- Unknown200
- Unknown156
- Unknown119
- Unknown104
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
MiNK Therapeutics Chosen for ARPA‑H Cell Therapy Initiative
MiNK Therapeutics was selected by ARPA‑H for a funded initiative that aims to develop room‑temperature cell therapies. The partnership gives the company access to research resources and potential collaboration with other biotech firms. This could accelerate the progress of MiNK’s cell‑based products and increase investor interest in the company’s pipeline.
MiNK Therapeutics Chosen for ARPA‑H Cell Therapy Initiative. MiNK Therapeutics was selected by ARPA‑H for a funded initiative that aims to develop room‑temperature cell therapies. The partnership gives the company access to research resources and potential collaboration with other biotech firms. This could accelerate the progress of MiNK’s cell‑based products and increase investor interest in the company’s pipeline.